7 days ago
VRTX
AnalystsTerence FlynnTerence Flynn's Stock Forecasts
AnalystsTerence Flynn
Sectors:
Analyst Ranking
Top 8%
#419 out of 5274 analysts
Average Return
+14.57%
Win Rate
55%75 out of 136
Risk vs Reward
Poor
Good
Terence Flynn's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Alumis IncALMS | +398.11% | $4.75 | $23.66 | 2025-08-14 - 2026-05-11 | Strong Buy |
Arcus Biosciences IncRCUS | +157.85% | $8.28 | $21.35 | 2025-05-08 - 2026-01-08 | Strong Buy |
Translate Bio IncTBIO1 | +147.91% | $15.07 | $37.36 | 2020-10-04 - 2021-09-14 | Strong Buy |
Blueprint Medicines CorpBPMC | +140.20% | $41.34 | $99.30 | 2017-03-12 - 2018-03-13 | Strong Buy |
Eli Lilly & CoLLY | +139.90% | $314.17 | $753.68 | 2023-02-28 - 2024-02-29 | Strong Buy |
Terence Flynn Analyst Color
Get additional color on Terence Flynn's coverage of popular stocks
12 days ago
ABBV
a month ago
VRTX
a month ago
RPRX
a month ago
LLY
2 months ago
ALMS
2 months ago
VRTX
4 months ago
NRIX
4 months ago
ALMS
5 months ago
BMY
5 months ago
MRK
5 months ago
GPCR
5 months ago
AMGN
5 months ago
ABBV
6 months ago
LLY
6 months ago
LLY
7 months ago
LLY
10 months ago
JNJ
10 months ago
RPRX
10 months ago
JNJ
10 months ago
LLY
a year ago
ABBV
a year ago
JNJ
a year ago
LLY
a year ago
JNJ
Terence Flynn's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Arcus Biosciences IncRCUS | 10 | Hold | $22.00 | -11.50% | Maintains | a day ago |
Vertex Pharmaceuticals IncVRTX | 6 | Strong Buy | $616.00 | +41.55% | Maintains | 7 days ago |
Abbvie IncABBV | 21 | Strong Buy | $278.00 | +37.09% | Maintains | 12 days ago |
Intellia Therapeutics IncNTLA | 6 | Hold | $15.00 | +4.02% | Maintains | 14 days ago |
United Therapeutics CorpUTHR | 12 | Hold | $519.00 | -8.93% | Maintains | a month ago |
Royalty Pharma PLCRPRX | 14 | Strong Buy | $63.00 | +21.97% | Maintains | a month ago |
Pfizer IncPFE | 22 | Hold | $28.00 | +8.49% | Maintains | a month ago |
Johnson & JohnsonJNJ | 29 | Strong Buy | $267.00 | +20.58% | Maintains | a month ago |
Eli Lilly & CoLLY | 23 | Strong Buy | $1,327.00 | +37.23% | Maintains | a month ago |
Biontech SeBNTX | 7 | Strong Buy | $126.00 | +34.99% | Maintains | a month ago |
Amgen IncAMGN | 13 | Hold | $326.00 | -1.09% | Maintains | a month ago |
Alumis IncALMS | 4 | Strong Buy | $38.00 | +60.61% | Maintains | 2 months ago |
Nurix Therapeutics IncNRIX | 7 | Strong Buy | $36.00 | +121.13% | Upgrades | 4 months ago |
Biohaven LtdBHVN | 5 | Strong Buy | $21.00 | +131.28% | Maintains | 4 months ago |
Bristol Myers Squibb CoBMY | 11 | Strong Sell | $37.00 | -33.54% | Maintains | 5 months ago |
Merck & Co IncMRK | 19 | Hold | $102.00 | -8.34% | Maintains | 5 months ago |
Structure Therapeutics IncGPCR | 2 | Strong Buy | $125.00 | +226.20% | Maintains | 5 months ago |
Organon & CoOGN | 11 | Hold | $9.00 | -32.48% | Maintains | 6 months ago |
Arvinas IncARVN | 8 | Hold | $11.00 | N/A | Maintains | a year ago |
Crispr Therapeutics AgCRSP | 7 | Strong Sell | $32.00 | N/A | Maintains | a year ago |
Blueprint Medicines CorpBPMC | 5 | Strong Buy | $168.00 | N/A | Maintains | 2 years ago |
C4 Therapeutics IncCCCC | 5 | Hold | $8.00 | N/A | Maintains | 2 years ago |
Revance Therapeutics IncRVNC | 7 | Hold | $12.00 | N/A | Maintains | 3 years ago |
Neuehealth IncNEUE | 1 | Strong Buy | $2,880.00 | N/A | Initiates Coverage On | 5 years ago |
Biogen IncBIIB | 2 | Hold | $436.00 | N/A | Maintains | 5 years ago |
Translate Bio IncTBIO1 | 1 | Strong Buy | $342.00 | N/A | Initiates Coverage On | 6 years ago |
Acceleron Pharma IncXLRN | 2 | Hold | $40.00 | N/A | Upgrades | 8 years ago |
Alnylam Pharmaceuticals IncALNY | 1 | Strong Buy | N/A | N/A | Upgrades | 9 years ago |
Kyntra Bio IncKYNB | 1 | Hold | N/A | N/A | Downgrades | 9 years ago |
Bioverativ IncBIVV | 1 | Hold | N/A | N/A | Downgrades | 9 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.